The innovation platform will employ expertise from the R&D team of the XJTLU Wisdom Lake Academy of Pharmacy. The research focuses of the platform include machine learning and AI-assisted drug design, new drug targets and mechanism of action study, drug synthesis and mass production, formulation, pharmacology and toxicology, neurobiology and model animal study, etc. The R&D team will collaboratively tackle the challenges of developing drug candidates to treat neurodegenerative diseases, improve public understanding of neurodegenerative diseases, and therefore discover novel approaches to treat neurodegenerative diseases. On the basis of platform development and project demands, the platform is recruiting research scientists and postdoctoral researchers, aiming to integrate high-quality biopharmaceutical resources worldwide, breakthrough the education mode of traditional universities, promote high-level of international collaborations, and advance talent recruitment and the aggregation of research outputs.
Research Areas
AI-based/Computer aided drug design
Drug targets and mechanism of action study
Drug synthesis and mass production
Formulation, Pharmacology and toxicology research
Neurobiology and model animal study
Structures and Functions
The Platform will establish a Laboratory Academic Committee to determine detailed research pathways and internal management regulations. Professor Lei Fu from the XJTLU Academy of Pharmacy has been appointed as the Director of the Laboratory Academic Committee, and Dr Min Xu, CEO of Pegbio Co. Ltd., has been appointed as the Co-director. The Academic Committee organizes annual meetings to review the annual progress, evaluate existing projects, conduct final project reviews, and map out the work for next year. Projects cannot be initiated until they are approved by the Academic Committee.
Overview
The innovation platform will employ expertise from the R&D team of the XJTLU Wisdom Lake Academy of Pharmacy. The research focuses of the platform include machine learning and AI-assisted drug design, new drug targets and mechanism of action study, drug synthesis and mass production, formulation, pharmacology and toxicology, neurobiology and model animal study, etc. The R&D team will collaboratively tackle the challenges of developing drug candidates to treat neurodegenerative diseases, improve public understanding of neurodegenerative diseases, and therefore discover novel approaches to treat neurodegenerative diseases. On the basis of platform development and project demands, the platform is recruiting research scientists and postdoctoral researchers, aiming to integrate high-quality biopharmaceutical resources worldwide, breakthrough the education mode of traditional universities, promote high-level of international collaborations, and advance talent recruitment and the aggregation of research outputs.
Research Areas
Structures and Functions
The Platform will establish a Laboratory Academic Committee to determine detailed research pathways and internal management regulations. Professor Lei Fu from the XJTLU Academy of Pharmacy has been appointed as the Director of the Laboratory Academic Committee, and Dr Min Xu, CEO of Pegbio Co. Ltd., has been appointed as the Co-director. The Academic Committee organizes annual meetings to review the annual progress, evaluate existing projects, conduct final project reviews, and map out the work for next year. Projects cannot be initiated until they are approved by the Academic Committee.